

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/594,293	08/07/2007	Jonathan Henry Ellis	PB60806	5674
<sup>20462</sup> GlaxoSmithKli	7590 08/03/2019 ne	0	EXAMINER	
GLOBAL PATENTS -US, UW2220			NATARAJAN, MEERA	
	P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939		ART UNIT	PAPER NUMBER
			1643	
				, <del></del>
			NOTIFICATION DATE	DELIVERY MODE
			08/03/2010	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US\_cipkop@gsk.com

		Application No.	Applicant(s)			
Response to Rule 312 Communication		10/594,293	ELLIS ET AL.			
respo	mise to Rule 312 Communication	Examiner	Art Unit			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address –						
1. ☑ The amendment filed on 29 July 2010 under 37 CFR 1.312 has been considered, and has been:						
a) ⊠ entered.						
b) 🔲	entered as directed to matters of form not affecting	g the scope of the invention	on.			
c) 🗌	disapproved because the amendment was filed after the payment of the issue fee.					
	Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.					
d) 🔲	disapproved. See explanation below.					
e) 🗌	entered in part. See explanation below.					
B.Crittenden						
			·			
	Subliching Divielon					
	Publishing Division					